<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>EXFORGE HCTÂ - amlodipine besylate, valsartan and hydrochlorothiazideÂ tablet, film coatedÂ </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use Exforge HCT safely and effectively. See full prescribing information for Exforge HCT.</span><br><span class="Bold">Exforge HCT (amlodipine, valsartan, hydrochlorothiazide) Tablets</span><br><span class="Bold">Initial U.S. Approval: 2009</span><br>
</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: AVOID USE IN PREGNANCY</span></h1>
<h1 class="Warning"><span class="Bold">When pregnancy is detected, discontinue Exforge HCT as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus. (5.1) </span></h1>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Warnings and Precautions: Acute Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> (5.11)
		Â Â Â Â Â 
	2/2011 </p></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: AVOID USE IN PREGNANCY</span></h1>
<h1 class="Warning"><span class="Bold">When pregnancy is detected, discontinue Exforge HCT as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus. (5.1) </span></h1>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><ul class="Disc">
<li>Exforge HCT is for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (1)<br>
</li>
<li>Not indicated for initial therapy </li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>Dose once-daily<br>
</li>
<li>Exforge HCT may be used as add-on/switch therapy for patients not adequately controlled on any two of the following antihypertensive classes: calcium channel blockers, angiotensin receptor blockers, and diuretics.<br>
</li>
<li>Exforge HCT may be substituted for its individually titrated components for patients on amlodipine, valsartan and hydrochlorothiazide (2).<br>
</li>
<li>The full blood pressure lowering effect was achieved 2 weeks after being on the maximal dose of Exforge HCT (2).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">Tablets: (amlodipine/valsartan/hydrochlorothiazide mg)   (<a href="#section-3">3</a>)</p>
<p class="Highlighta">5/160/12.5   (<a href="#section-3">3</a>)</p>
<p class="Highlighta">10/160/12.5   (<a href="#section-3">3</a>)</p>
<p class="Highlighta">5/160/25   (<a href="#section-3">3</a>)</p>
<p class="Highlighta">10/160/25   (<a href="#section-3">3</a>)</p>
<p class="Highlighta">10/320/25Â (3)  (<a href="#section-3">3</a>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">Anuria</span>; <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to sulfonamide-derived drugs (4)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Avoid fetal or neonatal exposure (5.1)<br>
</li>
<li>Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> with volume- or salt-depletion. Correct volume-depletion prior to administration (5.2)<br>
</li>
<li>Increased angina and/or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (5.3) <br>
</li>
<li>Avoid in patients with severely impaired hepatic (2.1, 5.4) or renal function (creatinine clearance â‰¤30 mL/min) (2.1, 5.5)<br>
</li>
<li>Observe for signs of fluid or <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> (5.10)<br>
</li>
<li>Thiazide diuretics may cause an exacerbation or activation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> (5.8)</li>
<li>Hydrochlorothiazide has been associated with acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> (5.11)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Most common adverse events (â‰¥2% incidence) are <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>.</span>  (<a href="#section-6">6</a>)</p>
<p class="Highlighta"><span><br><br>To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span>  (<a href="#section-6">6</a>)</p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Amlodipine: </span>  (<a href="#section-7">7</a>)</p>
<ul class="Disc"><li>If simvastatin is co-administered with amlodipine, do not exceed doses greater than 20 mg daily of simvastatin (7)</li></ul>
<p class="Highlighta"><span class="Bold">Hydrochlorothiazide</span>Â (7):Â   (<a href="#section-7">7</a>)</p>
<ul class="Disc">
<li>Alcohol, barbiturates, narcotics: Potentiation of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span><br>
</li>
<li>Antidiabetic drugs: Dosage adjustment of antidiabetic may be required<br>
</li>
<li>Cholestyramine and colestipol: Reduced absorption of thiazides <br>
</li>
<li>Corticosteroids, ACTH: <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span><br>
</li>
<li>Lithium: Reduced renal clearance and high risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> when used with diuretics. Should not be given with diuretics.<br>
</li>
<li>NSAIDs: Can reduce diuretic, natriuretic and antihypertensive effects of diuretics.</li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Pregnancy</span><span class="Bold">: </span><span class="Bold">Avoid use in pregnancy (5.1)</span>  (<a href="#section-8">8</a>)</p>
<p class="Highlighta"><span class="Bold">Nursing Mothers:</span> Avoid use while nursing â€“ discontinue either nursing or drug (8.3)  (<a href="#section-8">8</a>)</p>
<p class="Highlighta"><span class="Bold">Geriatric Patients</span><span class="Bold">: </span>No overall differences in the efficacy or safety of Exforge HCT was observed in this patient population, but greater sensitivity of some older individuals cannot be ruled out. (8.5)  (<a href="#section-8">8</a>)</p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 2/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">WARNING: AVOID USE IN PREGNANCY</span></a></h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1  INDICATIONS AND USAGE</span></a></h1>
<h1><a href="#section-2" class="toc"><span class="Bold">2</span><span class="Bold">  DOSAGE AND ADMINISTRATION</span></a></h1>
<h2><a href="#section-2.1" class="toc"><span class="Bold">2.1 General Considerations</span></a></h2>
<h2><a href="#section-2.2" class="toc"><span class="Bold">2.2 Add-on / Switch Therapy</span></a></h2>
<h2><a href="#section-2.3" class="toc"><span class="Bold">2.3 Replacement Therapy</span></a></h2>
<h1><a href="#section-3" class="toc"><span class="Bold">3  DOSAGE FORMS AND STRENGTHS</span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4  CONTRAINDICATIONS</span></a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">5  WARNINGS AND PRECAUTIONS</span></a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold">5.1 </span><span class="Bold">Fetal/Neonatal Morbidity and Mortality</span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold">5.2 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> in Volume- or Salt-Depleted Patients</span><span class="Bold">Â </span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold">5.3 Increased Angina and/or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="Bold">5.4 Impaired Hepatic Function</span></a></h2>
<h2><a href="#section-5.5" class="toc"><span class="Bold">5.5 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></span><span class="Bold">Â </span></a></h2>
<h2><a href="#section-5.6" class="toc"><span class="Bold">5.6 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></span></a></h2>
<h2><a href="#section-5.7" class="toc"><span class="Bold">5.7 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span></span></a></h2>
<h2><a href="#section-5.8" class="toc"><span class="Bold">5.8 <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic Lupus Erythematosus</span></span></a></h2>
<h2><a href="#section-5.9" class="toc"><span class="Bold">5.9 Lithium Interaction</span></a></h2>
<h2><a href="#section-5.10" class="toc"><span class="Bold">5.10 Electrolytes and Metabolic Imbalances</span></a></h2>
<h2><a href="#section-5.11" class="toc"><span class="Bold">5.11 Acute <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">Myopia</span> and Secondary Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></span></a></h2>
<h1><a href="#section-6" class="toc"><span class="Bold">6  ADVERSE REACTIONS</span></a></h1>
<h2><a href="#section-6.1" class="toc"><span class="Bold">6.1 Clinical Trials Experience</span></a></h2>
<h2><a href="#section-6.2" class="toc"><span class="Bold">6.2 Post-Marketing Experience</span></a></h2>
<h1><a href="#section-7" class="toc"><span class="Bold">7  DRUG INTERACTIONS</span></a></h1>
<h2><a href="#section-7.1" class="toc"><span class="Bold">7.1 Clinical Laboratory Test Findings</span></a></h2>
<h2><a href="#section-7.2" class="toc"><span class="Bold">7.3 Drug/Food Interactions</span></a></h2>
<h1><a href="#section-8" class="toc"><span class="Bold">8  USE IN SPECIFIC POPULATIONS</span><span class="Bold">Â </span></a></h1>
<h2><a href="#section-8.1" class="toc"><span class="Bold">8.1 </span><span class="Bold">Pregnancy</span></a></h2>
<h2><a href="#section-8.2" class="toc"><span class="Bold">8.3 </span><span class="Bold">Nursing Mothers</span></a></h2>
<h2><a href="#section-8.3" class="toc"><span class="Bold">8.4 </span><span class="Bold">Pediatric Use</span></a></h2>
<h2><a href="#section-8.4" class="toc"><span class="Bold">8.5 </span><span class="Bold">Geriatric Use</span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">10  OVERDOSAGE</span></a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">11  DESCRIPTION</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">12  CLINICAL PHARMACOLOGY</span></a></h1>
<h2><a href="#section-11.1" class="toc"><span class="Bold">12.1 </span><span class="Bold">Mechanism of Action</span></a></h2>
<h2><a href="#section-11.2" class="toc"><span class="Bold">12.2 </span><span class="Bold">Pharmacodynamics</span></a></h2>
<h2><a href="#section-11.3" class="toc"><span class="Bold">12.3 </span><span class="Bold">Pharmacokinetics</span></a></h2>
<h1><a href="#section-12" class="toc"><span class="Bold">13  NONCLINICAL TOXICOLOGY</span></a></h1>
<h2><a href="#section-12.1" class="toc"><span class="Bold">13.1 </span><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</span></a></h2>
<h2><a href="#section-12.2" class="toc"><span class="Bold">13.3 </span><span class="Bold">Developmental Toxicity</span></a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">14 </span><span class="Bold">Â </span><span class="Bold">CLINICAL STUDIES</span></a></h1>
<h1><a href="#section-14" class="toc"><span class="Bold">16  HOW SUPPLIED/STORAGE AND HANDLING</span></a></h1>
<h1><a href="#section-15" class="toc"><span class="Bold">17  PATIENT COUNSELING INFORMATION</span></a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="section-1"></a><p></p>
<h1><span class="Bold">WARNING: AVOID USE IN PREGNANCY</span></h1>
<p class="First"><span class="Bold">When pregnancy is detected, discontinue Exforge HCT as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus [see </span><span class="Bold Italics">Warnings and Precautions</span><span class="Bold"> (5.1)]. </span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1><span class="Bold">1  INDICATIONS AND USAGE</span></h1>
<p class="First">Exforge HCT (amlodipine, valsartan, hydrochlorothiazide) is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
<p>This fixed combination drug is not indicated for the initial therapy of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> [see <span class="Italics">Dosage and Administration</span> (2)].</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1>
<span class="Bold">2</span><span class="Bold">  DOSAGE AND ADMINISTRATION</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2><span class="Bold">2.1 General Considerations</span></h2>
<p class="First">Dose once-daily. The dosage may be increased after two weeks of therapy. The full blood pressure lowering effect was achieved 2 weeks after being on the maximal dose of Exforge HCT. The maximum recommended dose of Exforge HCT is 10/320/25 mg.</p>
<p>Exforge HCT may be administered with or without food.</p>
<p>No initial dosage adjustment is required for elderly patients.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span></span><span class="Bold">: </span>The usual regimens of therapy with Exforge HCT may be followed if the patientâ€™s creatinine clearance is &gt;30 mL/min. In patients with more severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, loop diuretics are preferred to thiazides, so avoid use of Exforge HCT  [see <span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></span> (5.5)].</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span></span>: Avoid Exforge HCT in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. In patients with lesser degrees of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, monitor for worsening of hepatic or renal function and adverse reactions [see <span class="Italics">Impaired Hepatic Function </span>(5.4)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<h2><span class="Bold">2.2 Add-on / Switch Therapy</span></h2>
<p class="First">Exforge HCT may be used for patients not adequately controlled on any two of the following antihypertensive classes: calcium channel blockers, angiotensin receptor blockers, and diuretics.</p>
<p>A patient who experiences dose-limiting adverse reactions to an individual component while on any dual combination of the components of Exforge HCT may be switched to Exforge HCT containing a lower dose of that component to achieve similar blood pressure reductions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3"></a><p></p>
<h2><span class="Bold">2.3 Replacement Therapy</span></h2>
<p class="First">Exforge HCT may be substituted for the individually titrated components.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1><span class="Bold">3  DOSAGE FORMS AND STRENGTHS</span></h1>
<ul class="Disc">
<li>5 mg amlodipine /160 mg valsartan /12.5 mg hydrochlorothiazide Tablets â€“ White, non-scored, film-coated tablet, ovaloid, biconvex with beveled edge with debossing â€œNVRâ€? on one side and â€œVCLâ€? on the other side.<br>
</li>
<li>10 mg amlodipine /160 mg valsartan /12.5 mg hydrochlorothiazide Tablets â€“ <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">Pale</span> yellow, non-scored, film-coated tablet, ovaloid, biconvex with beveled edge with debossing â€œNVRâ€? on one side and â€œVDLâ€? on the other side.<br>
</li>
<li>5 mg amlodipine /160 mg valsartan /25 mg hydrochlorothiazide Tablets â€“ Yellow, non-scored, film-coated tablet, ovaloid, biconvex with beveled edge with debossing â€œNVRâ€? on one side and â€œVELâ€? on the other side.<br>
</li>
<li>10 mg amlodipine /160 mg valsartan /25 mg hydrochlorothiazide Tablets â€“ Brown-yellow, non-scored, film-coated tablet, ovaloid, biconvex with beveled edge with debossing â€œNVRâ€? on one side and â€œVHLâ€? on the other side.<br>
</li>
<li>10 mg amlodipine /320 mg valsartan /25 mg hydrochlorothiazide Tablets â€“ Brown-yellow, non-scored, film-coated tablet, ovaloid, biconvex with beveled edge with debossing â€œNVRâ€? on one side and â€œVFLâ€? on the other side.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1><span class="Bold">4  CONTRAINDICATIONS</span></h1>
<p class="First">Because of the hydrochlorothiazide component, Exforge HCT is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other sulfonamide-derived drugs.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1><span class="Bold">5  WARNINGS AND PRECAUTIONS</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>
<span class="Bold">5.1 </span><span class="Bold">Fetal/Neonatal Morbidity and Mortality</span>
</h2>
<p class="First">Exforge HCT can cause harm to the fetus when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p>
<p>Drugs that act on the renin angiotensin system can cause fetal and neonatal morbidity and mortality when used in pregnancy.  In several dozen published cases, ACE inhibitor use during the second and third trimesters of pregnancy was associated with fetal and neonatal injury, including <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, neonatal skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, reversible or <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">irreversible renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> [see <span class="Italics">Use in Specific Populations </span>(8.1)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>
<span class="Bold">5.2 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> in Volume- or Salt-Depleted Patients</span><span class="Bold">Â </span>
</h2>
<p class="First">Excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, including <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, was seen in 1.7% of patients treated with the maximum dose of Exforge HCT (10/320/25 mg) compared to 1.8% of valsartan/HCTZ (320/25 mg) patients, 0.4% of amlodipine/valsartan (10/320 mg) patients, and 0.2% of HCTZ/amlodipine (25/10 mg) patients in a controlled trial in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncomplicated hypertension</span>. In patients with an activated renin-angiotensin system, such as volume-Â or salt-depleted patients receiving high doses of diuretics, symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> may occur in patients receiving angiotensin receptor blockers. Correct this condition prior to administration of Exforge HCT.</p>
<p>Exforge HCT has not been studied in patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, or in patients undergoing surgery or dialysis. Patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> patients given valsartan commonly have some reduction in blood pressure, but discontinuation of therapy because of continuing symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> usually is not necessary when dosing instructions are followed. In controlled trials in <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> patients, the incidence of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in valsartan-treated patients was 5.5% compared to 1.8% in placebo-treated patients. In the Valsartan in <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span> Trial (VALIANT), <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> patients led to permanent discontinuation of therapy in 1.4% of valsartan-treated patients and 0.8% of captopril-treated patients.</p>
<p>Since the vasodilation induced by amlodipine is gradual in onset, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">acute hypotension</span> has rarely been reported after oral administration. Do not initiate treatment with Exforge HCT in patients with aortic or <span class="product-label-link" type="condition" conceptid="315273" conceptname="Mitral valve stenosis">mitral stenosis</span> or obstructive <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">hypertrophic cardiomyopathy</span>.</p>
<p>If excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs with Exforge HCT, the patient should be placed in a supine position and, if necessary, given an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once the blood pressure has stabilized.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3"></a><p></p>
<h2><span class="Bold">5.3 Increased Angina and/or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span></h2>
<p class="First">Rarely, patients, particularly those with severe obstructive <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, have developed documented increased frequency, duration or severity of angina or <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> upon starting calcium channel blocker therapy or at the time of dosage increase. The mechanism of this effect has not been elucidated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.4"></a><p></p>
<h2><span class="Bold">5.4 Impaired Hepatic Function</span></h2>
<p class="First">Amlodipine is extensively metabolized by the liver and the plasma elimination half-life (tÂ½) is 56 hours in patients with impaired hepatic function.</p>
<p>As the majority of valsartan is eliminated in the bile, patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, including patients with biliary obstructive disorders, showed lower valsartan clearance (higher AUCs).</p>
<p>In patients with impaired hepatic function or progressive liver disease, minor alterations of fluid and electrolyte balance, such as those resulting from diuretic use,  may precipitate <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span>.</p>
<p>Therefore, avoid the use of Exforge HCT in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. When administering Exforge HCT to patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, including patients with biliary obstructive disorders, monitor for worsening of hepatic or renal function, including fluid status and electrolytes, and adverse reactions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.5"></a><p></p>
<h2>
<span class="Bold">5.5 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></span><span class="Bold">Â </span>
</h2>
<p class="First">As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists has been associated with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and/or progressive <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> and (rarely) with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Similar outcomes have been reported with valsartan.</p>
<p>In studies of ACE inhibitors in hypertensive patients with unilateral or <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">bilateral renal artery stenosis</span>, increases in serum creatinine or blood urea nitrogen have been reported. In a 4-day trial of valsartan in 12 hypertensive patients with <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">unilateral renal artery stenosis</span>, no significant increases in serum creatinine or blood urea nitrogen were observed. There has been no long-term use of valsartan in patients with unilateral or <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">bilateral renal artery stenosis</span>, but an effect similar to that seen with ACE inhibitors should be anticipated.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, thiazides may precipitate <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>. Cumulative effects of the drug may develop in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
<p>Avoid use of Exforge HCT in severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (creatinine clearance â‰¤30 mL/min). The usual regimens of therapy with Exforge HCT may be followed if the patientâ€™s creatinine clearance is &gt;30 mL/min.</p>
<p>There is no experience in the use of Exforge HCT in patients with a recent kidney transplant.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.6"></a><p></p>
<h2><span class="Bold">5.6 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></span></h2>
<p class="First">Exforge HCT has not been studied in patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
<p><span class="Bold">Studies with amlodipine</span>: In general, calcium channel blockers should be used with close monitoring, including close follow-up of fluid status, electrolytes, renal function, and blood pressure in patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Amlodipine (5-10 mg per day) has been studied in a placebo-controlled trial of 1,153 patients with NYHA Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> on stable doses of ACE inhibitor, digoxin, and diuretics. Follow-up was at least 6 months, with a mean of about 14 months. There was no overall adverse effect on survival or cardiac morbidity (as defined by life-threatening <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, or hospitalization for worsened <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>). Amlodipine has been compared to placebo in four 8-12 week studies of patients with NYHA class II/III <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, involving a total of 697 patients. In these studies, there was no evidence of worsened <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> based on measures of exercise tolerance, NYHA classification, symptoms, or LVEF.</p>
<p><span class="Bold">Studies with valsartan:</span> Some patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> have developed increases in blood urea nitrogen, serum creatinine, and potassium on valsartan. These effects are usually minor and transient, and they are more likely to occur in patients with pre-existing <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Dosage reduction and/or discontinuation of the diuretic and/or valsartan may be required. In the Valsartan <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> Trial, in which 93% of patients were on concomitant ACE inhibitors, treatment was discontinued for elevations in creatinine or potassium (total of 1.0% on valsartan vs. 0.2% on placebo). In the Valsartan in <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute Myocardial Infarction</span> Trial (VALIANT), discontinuation due to various types of renal dysfunction occurred in 1.1% of valsartan-treated patients and 0.8% of captopril-treated patients. Evaluation of patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> should always include assessment of renal function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.7"></a><p></p>
<h2><span class="Bold">5.7 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span></span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> to hydrochlorothiazide may occur in patients with or without a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, but are more likely in patients with such a history.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.8"></a><p></p>
<h2><span class="Bold">5.8 <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic Lupus Erythematosus</span></span></h2>
<p class="First">Thiazide diuretics have been reported to cause exacerbation or activation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.9"></a><p></p>
<h2><span class="Bold">5.9 Lithium Interaction</span></h2>
<p class="First">Lithium generally should not be given with thiazides [see <span class="Italics">Drug Interactions, Hydrochlorothiazide, Lithium</span> (7)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.10"></a><p></p>
<h2><span class="Bold">5.10 Electrolytes and Metabolic Imbalances</span></h2>
<p class="First"><span class="Bold">Amlodipine -Valsartan - Hydrochlorothiazide</span></p>
<p>In the controlled trial of Exforge HCT in moderate to severe hypertensive patients, the incidence of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (serum potassium &lt;3.5 mEq/L) at any time post-baseline with the maximum dose of Exforge HCT (10/320/25 mg) was 10% compared to 25% with HCTZ/amlodipine (25/10 mg), 7% with valsartan/HCTZ (320/25 mg), and 3% with amlodipine/valsartan (10/320 mg). One patient (0.2%) discontinued therapy due to an adverse event of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> in each of the Exforge HCT and HCTZ/amlodipine groups. The incidence of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (serum potassium &gt;5.7 mEq/L) was 0.4% with Exforge HCT compared to 0.2-0.7% with the dual therapies. Monitor serum electrolytes periodically based on Exforge HCT use and other factors such as renal function, other medications, or history of prior <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalances</span>.</p>
<p><span class="Bold">Hydrochlorothiazide</span>Â </p>
<p>All patients receiving thiazide therapy should be observed for clinical signs of fluid or <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>: <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4289304" conceptname="Hypochloremic alkalosis">hypochloremic alkalosis</span>, and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. Serum and urine electrolyte determinations are particularly important when the patient is <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> excessively or receiving parenteral fluids. Warning signs or symptoms of fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, irrespective of cause, include dryness of mouth, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, muscular <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may develop, especially with brisk <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, when severe cirrhosis is present, or after prolonged therapy.</p>
<p>Interference with adequate oral electrolyte intake will also contribute to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may cause <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span> and may also sensitize or exaggerate the response of the heart to the toxic effects of digitalis (e.g., increased ventricular <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>).</p>
<p>Although any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (as in liver disease or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>), chloride replacement may be required in the treatment of <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">metabolic alkalosis</span>.</p>
<p>Dilutional <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> may occur in edematous patients in hot weather; appropriate therapy is water restriction, rather than administration of salt except in rare instances when the <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> is life-threatening. In actual <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span>, appropriate replacement is the therapy of choice.</p>
<p><span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span> may occur or frank <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> may be precipitated in certain patients receiving thiazide therapy.</p>
<p>In diabetic patients, dosage adjustments of insulin or oral hypoglycemic agents may be required. <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> may occur with thiazide diuretics. Thus <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span> mellitus may become manifest during thiazide therapy.</p>
<p>The antihypertensive effects of the drug may be enhanced in the postsympathectomy patient.</p>
<p>If progressive <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> becomes evident, consider withholding or discontinuing Exforge HCT therapy or substituting other antihypertensive therapy.</p>
<p>Thiazides have been shown to increase the urinary excretion of magnesium; this may result in <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>.</p>
<p>Thiazides may decrease urinary calcium excretion. Thiazides may cause intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Marked <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> may be evidence of hidden <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span>. Exforge HCT should be discontinued or non-thiazide antihypertensive therapy substituted before carrying out tests for parathyroid function.</p>
<p>Increases in <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglyceride levels may be associated with thiazide diuretic therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.11"></a><p></p>
<h2><span class="Bold">5.11 Acute <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">Myopia</span> and Secondary Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></span></h2>
<p class="First"><span class="Xmchange"></span>Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">myopia</span> and acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.  Symptoms include acute onset of decreased visual acuity or <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> and typically occur within hours to weeks of drug initiation.  Untreated acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> can lead to permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span>.  The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible.   Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled.  Risk factors for developing acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> may include a history of sulfonamide or <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">penicillin allergy</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1><span class="Bold">6  ADVERSE REACTIONS</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2><span class="Bold">6.1 Clinical Trials Experience</span></h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.</p>
<p>In the controlled trial of Exforge HCT, where only the maximum dose (10/320/25 mg) was evaluated, safety data were obtained in 582 patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Adverse reactions have generally been mild and transient in nature and have only infrequently required discontinuation of therapy.</p>
<p>The overall frequency of adverse reactions was similar between men and women, younger (&lt;65 years) and older (<span class="Underline">&gt;</span>65 years) patients, and black and white patients. In the active controlled clinical trial, discontinuation because of adverse events occurred in 4.0% of patients treated with Exforge HCT 10/320/25 mg compared to 2.9% of patients treated with valsartan/HCTZ 320/25 mg, 1.6% of patients treated with amlodipine/valsartan 10/320 mg, and 3.4% of patients treated with HCTZ/amlodipine 25/10 mg. The most common reasons for discontinuation of therapy with Exforge HCT were <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (1.0%) and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (0.7%).</p>
<p>The most frequent adverse events that occurred in the active controlled clinical trial in at least 2% of patients treated with Exforge HCT are presented in the table below:</p>
<a name="if36040b2-5fb4-4800-8897-878ce88ef857"></a><table>
<col width="108">
<col width="94">
<col width="72">
<col width="72">
<col width="72">
<tbody class="Headless">
<tr class="First">
<td>
<br><span class="Bold">Preferred Term</span>
</td>
<td align="center">
<span class="Bold">Aml/Val/HCTZ</span><span class="Bold"><br>10/320/25Â mg</span><span class="Bold"><br>N=582</span><span class="Bold"><br>nÂ (%)</span>
</td>
<td align="center">
<span class="Bold">Val/HCTZ</span><span class="Bold"><br>320/25Â mg</span><span class="Bold"><br>N=559</span><span class="Bold"><br>nÂ (%)</span>
</td>
<td align="center">
<span class="Bold">Aml/Val</span><span class="Bold"><br>10/320Â mg</span><span class="Bold"><br>N=566</span><span class="Bold"><br>nÂ (%)</span>
</td>
<td align="center">
<span class="Bold">HCTZ/Aml</span><span class="Bold"><br>25/10Â mg</span><span class="Bold"><br>N=561</span><span class="Bold"><br>nÂ (%)</span>
</td>
</tr>
<tr>
<td class="Toprule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></span></td>
<td class="Toprule" align="center"><span class="Bold">48 (8.2)</span></td>
<td class="Toprule" align="center"><span class="Bold">40 (7.2)</span></td>
<td class="Toprule" align="center"><span class="Bold">14 (2.5)</span></td>
<td class="Toprule" align="center"><span class="Bold">23 (4.1)</span></td>
</tr>
<tr>
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> </span></td>
<td align="center"><span class="Bold">38 (6.5)</span></td>
<td align="center"><span class="Bold">  8 (1.4)</span></td>
<td align="center">
<span class="Bold">  65 (11.5</span><span class="Bold">)</span>
</td>
<td align="center"><span class="Bold"> 63 (11.2)</span></td>
</tr>
<tr>
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></span></td>
<td align="center"><span class="Bold">30 (5.2)</span></td>
<td align="center"><span class="Bold">31 (5.5)</span></td>
<td align="center"><span class="Bold">30 (5.3)</span></td>
<td align="center"><span class="Bold">40 (7.1)</span></td>
</tr>
<tr>
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></span></td>
<td align="center"><span class="Bold">13 (2.2)</span></td>
<td align="center"><span class="Bold">  5 (0.9)</span></td>
<td align="center"><span class="Bold"> 6 (1.1)</span></td>
<td align="center"><span class="Bold"> 2 (0.4)</span></td>
</tr>
<tr>
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></span></td>
<td align="center"><span class="Bold">13 (2.2)</span></td>
<td align="center"><span class="Bold">15 (2.7)</span></td>
<td align="center"><span class="Bold">12 (2.1)</span></td>
<td align="center"><span class="Bold"> 8 (1.4)</span></td>
</tr>
<tr>
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasms</span></span></td>
<td align="center"><span class="Bold">13 (2.2)</span></td>
<td align="center"><span class="Bold">  7 (1.3)</span></td>
<td align="center"><span class="Bold">  7 (1.2)</span></td>
<td align="center"><span class="Bold"> 5 (0.9)</span></td>
</tr>
<tr>
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></span></td>
<td align="center"><span class="Bold">12 (2.1)</span></td>
<td align="center"><span class="Bold">13 (2.3)</span></td>
<td align="center"><span class="Bold">  5 (0.9)</span></td>
<td align="center"><span class="Bold">12 (2.1)</span></td>
</tr>
<tr>
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></span></td>
<td align="center"><span class="Bold">12 (2.1)</span></td>
<td align="center"><span class="Bold">  7 (1.3)</span></td>
<td align="center"><span class="Bold">10 (1.8)</span></td>
<td align="center"><span class="Bold">12 (2.1)</span></td>
</tr>
<tr class="Last">
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></span></td>
<td align="center"><span class="Bold">12 (2.1)</span></td>
<td align="center"><span class="Bold">13 (2.3)</span></td>
<td align="center"><span class="Bold">13 (2.3)</span></td>
<td align="center"><span class="Bold">12 (2.1)</span></td>
</tr>
</tbody>
</table>
<p>Orthostatic events (<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> and postural <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>) were seen in 0.5% of patients. Other adverse reactions that occurred in clinical trials with Exforge HCT (&gt;0.2%) are listed below. It cannot be determined whether these events were causally related to Exforge HCT.</p>
<p><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>: <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span></p>
<p>Ear and Labyrinth Disorders: <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span></p>
<p><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span>: <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span></p>
<p><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4099176" conceptname="Toothache">toothache</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">hemorrhoids</span></p>
<p>General Disorders and Administration Site Conditions: <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4164649" conceptname="Non-cardiac chest pain">non-cardiac chest pain</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span></p>
<p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span>: <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4103655" conceptname="Dental abscess">tooth abscess</span>, <span class="product-label-link" type="condition" conceptid="201218" conceptname="Epidemic vomiting syndrome">gastroenteritis viral</span>, <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span></p>
<p>Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span> and Procedural Complications: <span class="product-label-link" type="condition" conceptid="134520" conceptname="Crushing injury of back">back injury</span>, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">contusion</span>, <span class="product-label-link" type="condition" conceptid="30234" conceptname="Neck sprain">joint sprain</span>, <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">procedural pain</span></p>
<p>Investigations: <span class="product-label-link" type="condition" conceptid="4148593" conceptname="Blood urate raised">blood uric acid increased</span>, <span class="product-label-link" type="condition" conceptid="4294804" conceptname="Creatine kinase">blood creatine phosphokinase</span> increased, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decreased</span></p>
<p>Metabolism and Nutrition Disorders: <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalaemia</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span></p>
<p>Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span>: <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, musculoskeletal <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">musculoskeletal stiffness</span>, <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>, <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span>, <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>, <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendonitis</span></p>
<p><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>: parasthesia, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="380094" conceptname="Carpal tunnel syndrome">carpal tunnel syndrome</span>, <span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">disturbance in attention</span>, <span class="product-label-link" type="condition" conceptid="4250121" conceptname="Dizziness on standing up">dizziness postural</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, head <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4172302" conceptname="Sinus headache">sinus headache</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span></p>
<p>Psychiatric Disorders: <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span></p>
<p>Renal and Urinary Disorders: <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">pollakiuria</span></p>
<p>Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span>: <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span></p>
<p>Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span>: <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></p>
<p>Skin and Subcutaneous Tissue Disorders: <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">night sweats</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p>
<p><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span></p>
<p>Isolated cases of the following clinically notable adverse reactions were also observed in clinical trials: <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>.</p>
<p><span class="Bold">Amlodipine</span></p>
<p>Amlodipine has been evaluated for safety in more than 11,000 patients in U.S. and foreign clinical trials. Other adverse reactions not listed above that have been reported in &lt;1% but &gt;0.1% of patients in controlled clinical trials or under conditions of open trials or marketing experience where a causal relationship is uncertain were:</p>
<p>Cardiovascular: <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> (including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>), <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4124836" conceptname="Peripheral ischemia">peripheral ischemia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span></p>
<p>Central and Peripheral Nervous System: <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy peripheral</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> </p>
<p>Gastrointestinal: <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, gingival <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span></p>
<p>General: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span></p>
<p>Musculoskeletal System: <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthrosis</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span></p>
<p>Psychiatric: <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> (male and female), <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span></p>
<p>Skin and Appendages: <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculopapular</p>
<p>Special Senses: <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span></p>
<p>Urinary System: micturition frequency, micturition disorder, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span></p>
<p>Autonomic Nervous System: <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating increased</span></p>
<p>Metabolic and Nutritional: <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span></p>
<p>Hemopoietic: <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></p>
<p>Other adverse reactions reported with amlodipine at a frequency of â‰¤0.1% of patients include: <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, pulse irregularity, <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, skin dryness, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">parosmia</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>, abnormal visual accommodation, and <span class="product-label-link" type="condition" conceptid="4180937" conceptname="Xerophthalmia">xerophthalmia</span>. Other reactions occurred sporadically and cannot be distinguished from medications or concurrent disease states such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and angina.</p>
<p>Adverse reactions reported for amlodipine for indications other than <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> may be found in its full prescribing information.</p>
<p><span class="Bold">Valsartan</span><span class="Bold">Â Â </span></p>
<p>Valsartan has been evaluated for safety in more than 4,000 hypertensive patients in clinical trials. In trials in which valsartan was compared to an ACE inhibitor with or without placebo, the incidence of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">dry cough</span> was significantly greater in the ACE inhibitor group (7.9%) than in the groups who received valsartan (2.6%) or placebo (1.5%). In a 129 patient trial limited to patients who had <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">dry cough</span> when they had previously received ACE inhibitors, the incidences of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> in patients who received valsartan, HCTZ, or lisinopril were 20%, 19%, and 69% respectively (p&lt;0.001).</p>
<p>Other adverse reactions, not listed above, occurring in &gt;0.2% of patients in controlled clinical trials with valsartan are:</p>
<p>Digestive: <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span></p>
<p>Respiratory: <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span></p>
<p>Urogenital: <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span></p>
<p>Adverse reactions reported for valsartan for indications other than <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> may be found in the prescribing information for Diovan.</p>
<p><span class="Bold">Hydrochlorothiazide</span></p>
<p>Other adverse reactions not listed above that have been reported with hydrochlorothiazide, without regard to causality, are listed below:</p>
<p>Body as a Whole<span class="Italics">: </span><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></p>
<p>Digestive: <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (intrahepatic <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>), <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">sialadenitis</span>, cramping, <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span></p>
<p>Hematologic: <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span></p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>: <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, necrotizing <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">angiitis</span> (<span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> and <span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">cutaneous vasculitis</span>), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> including <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span></p>
<p>Metabolic: <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span></p>
<p>Nervous System/Psychiatric: <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span></p>
<p>Renal: <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, renal dysfunction, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span></p>
<p>Skin: <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> including <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span></p>
<p>Special Senses: transient <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4168789" conceptname="Xanthopsia">xanthopsia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2><span class="Bold">6.2 Post-Marketing Experience</span></h2>
<p class="First"><span class="Bold">Amlodipine</span></p>
<p>With amlodipine, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span> has been reported infrequently and a causal relationship is uncertain. <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span> and hepatic enzyme elevations (mostly consistent with <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span> or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>), in some cases severe enough to require hospitalization, have been reported in association with use of amlodipine.</p>
<p><span class="Bold">Valsartan</span></p>
<p>The following additional adverse reactions have been reported in post-marketing experience with valsartan or valsartan/hydrochlorothiazide:</p>
<p>Blood and Lymphatic: There are very rare reports of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>: There are rare reports of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
<p>Digestive: Elevated liver enzymes and very rare reports of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span></p>
<p>Renal: <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired renal function</span></p>
<p>Clinical Laboratory Tests: <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></p>
<p>Dermatologic: <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></p>
<p>Vascular: <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">Vasculitis</span></p>
<p>Nervous System: <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> </p>
<p>Rare cases of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported in patients receiving angiotensin II receptor blockers. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1><span class="Bold">7  DRUG INTERACTIONS</span></h1>
<p class="First">No drug interaction studies have been conducted with Exforge HCT and other drugs, although studies have been conducted with the individual components. A pharmacokinetic drug-drug interaction study has been conducted to address the potential for <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> between the triple combination, Exforge HCT, and the corresponding three double combinations. No clinically relevant interaction was observed.</p>
<p><span class="Bold">Amlodipine</span></p>
<p>In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs.</p>
<p>Cimetidine: Co-administration of amlodipine with cimetidine did not alter the pharmacokinetics of amlodipine.</p>
<p>Grapefruit juice: Co-administration of 240 mL of grapefruit juice with a single oral dose of amlodipine 10 mg in 20 healthy volunteers had no significant effect on the pharmacokinetics of amlodipine.</p>
<p>Magnesium and aluminum hydroxide (antacid): Co-administration of the magnesium and aluminum hydroxide antacid with a single dose of amlodipine had no significant effect on the pharmacokinetics of amlodipine.</p>
<p>Sildenafil: A single 100 mg dose of sildenafil in subjects with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> had no effect on the pharmacokinetic parameters of amlodipine. When amlodipine and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect.</p>
<p>Atorvastatin: Co-administration of multiple 10 mg doses of amlodipine with 80 mg of atorvastatin resulted in no significant change in the steady state pharmacokinetic parameters of atorvastatin.</p>
<p>Digoxin: Co-administration of amlodipine with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers.</p>
<p>Warfarin: Co-administration of amlodipine with warfarin did not change the warfarin <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> response time.</p>
<p>Simvastatin: Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone.  Limit the dose of simvastatin in patients on amlodipine to 20 mg daily.</p>
<p><span class="Bold">Valsartan</span></p>
<p>No clinically significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> were observed when valsartan was co-administered with amlodipine, atenolol, cimetidine, digoxin, furosemide, glyburide, hydrochlorothiazide, or indomethacin. The valsartan-atenolol combination was more antihypertensive than either component, but it did not lower the heart rate more than atenolol alone.</p>
<p>In vitro metabolism studies have indicated that CYP450 mediated drug interaction between valsartan and co-administered drugs are unlikely because of the low extent of metabolism [see <span class="Italics">Pharmacokinetics </span><span class="Italics">â€“</span><span class="Italics"> Valsartan</span><span class="Italics">,</span><span class="Italics">Â </span>(12.3)].</p>
<p>Co-administration of valsartan and warfarin did not change the pharmacokinetics of valsartan or the time-course of the anticoagulant properties of warfarin.</p>
<p>As with other drugs that block angiotensin II or its effects, concomitant use of potassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> patients to increases in serum creatinine.</p>
<p><span class="Bold">Hydrochlorothiazide</span></p>
<p>When administered concurrently the following drugs may interact with thiazide diuretics:</p>
<p><span class="Italics">Alcohol, barbiturates, or narcotics</span>: Potentiation of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> may occur.</p>
<p><span class="Italics">Antidiabetic drugs (oral agents and insulin):</span> Dosage adjustment of the antidiabetic drug may be required.</p>
<p><span class="Italics">Other antihype</span><span class="Italics">rtensive drugs</span>: Additive effect or potentiation.</p>
<p><span class="Italics">Cholestyramine and colestipol resins:</span> Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43% respectively.</p>
<p><span class="Italics">Corticosteroids, ACTH: </span>Intensified <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span>, particularly <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
<p><span class="Italics">Pressor amines</span> (e.g., norepinephrine): Possible decreased response to pressor amines but not sufficient to preclude their use.</p>
<p><span class="Italics">Skeletal muscle relaxants, nondepolarizing</span> (e.g., tubocurarine): Possible increased responsiveness to the muscle relaxant.</p>
<p><span class="Italics">Lithium</span>: Should not generally be given with diuretics. Diuretic agents reduce the renal clearance of lithium and add a high risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. Refer to the package insert for lithium preparations before use of such preparations with Exforge HCT.</p>
<p><span class="Italics">Non-steroidal anti-inflammatory drugs</span>: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.</p>
<p><span class="Italics">Carbamazepine</span>: May lead to symptomatic <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2><span class="Bold">7.1 Clinical Laboratory Test Findings</span></h2>
<p class="First">Clinical laboratory test findings for Exforge HCT were obtained in a controlled trial of Exforge HCT administered at the maximal dose of 10/320/25 mg compared to maximal doses of dual therapies, i.e. valsartan/HCTZ 320/25 mg, amlodipine/valsartan 10/320 mg, and HCTZ/amlodipine 25/10 mg. Findings for the components of Exforge HCT were obtained from other trials.</p>
<p><span class="Bold Italics">Creatinine</span><span class="Bold Italics">: </span>In hypertensive patients, greater than 50% increases in creatinine occurred in 2.1% of Exforge HCT patients compared to 2.4% of valsartan/HCTZ patients,Â 0.7% of amlodipine/valsartan patients, and 1.8% of HCTZ/amlodipine patients.</p>
<p>In <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> patients, greater than 50% increases in creatinine were observed in 3.9% of valsartan-treated patients compared to 0.9% of placebo-treated patients. In post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> patients, doubling of serum creatinine was observed in 4.2% of valsartan-treated patients and 3.4% of captopril-treated patients.</p>
<p><span class="Bold Italics">Liver Function Tests</span><span class="Bold Italics">: </span>Occasional elevations (greater than 150%) of liver chemistries occurred in Exforge HCT-treated patients.</p>
<p><span class="Bold Italics">Blood Urea Nitrogen (BUN)</span><span class="Bold Italics">: </span>In hypertensive patients, greater than 50% increases in BUN were observed in 30% of Exforge HCT-treated patients compared to 29% of valsartan/HCTZ patients,Â 15.8% of amlodipine/valsartan patients, and 18.5% of HCTZ/amlodipine patients. The majority of BUN values remained within normal limits.</p>
<p>In <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> patients, greater than 50% increases in BUN were observed in 17% of valsartan-treated patients compared to 6% of placebo-treated patients.</p>
<p><span class="Bold Italics">Serum Electrolytes (Potassium)</span><span class="Bold Italics">: </span>In hypertensive patients, greater than 20% decreases in serum potassium were observed in 6.5% of Exforge HCT-treated patients compared to 3.3% of valsartan/HCTZ patients,Â 0.4% of amlodipine/valsartan patients, and 19.3% of HCTZ/amlodipine patients. Greater than 20% increases in potassium were observed in 3.5% of Exforge HCT-treated patients compared to 2.4% of valsartan/HCTZ patients,Â 6.2% of amlodipine/valsartan patients, and 2.2% of HCTZ/amlodipine patients.</p>
<p>In <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> patients, greater than 20% increases in serum potassium were observed in 10% of valsartan-treated patients compared to 5.1% of placebo-treated patients [see <span class="Italics">Warnings and Precautions, Electrolytes and Metabolic Imbalances </span>(5.10)].</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (&lt;1500/L) was observed in 1.9% of patients treated with valsartan and 0.8% of patients treated with placebo.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2><span class="Bold">7.3 Drug/Food Interactions</span></h2>
<p class="First">The bioavailability of amlodipine, valsartan, and HCTZ were not altered when Exforge HCT was administered with food.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>
<span class="Bold">8  USE IN SPECIFIC POPULATIONS</span><span class="Bold">Â </span>
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2>
<span class="Bold">8.1 </span><span class="Bold">Pregnancy</span>
</h2>
<p class="First">Pregnancy Category D</p>
<p>Valsartan, like other drugs that act on the renin angiotensin system, can cause fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> when used during the second or third trimester of pregnancy. If Exforge HCT is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p>
<p>Angiotensin II receptor antagonists, like valsartan, and angiotensin converting enzyme (ACE) inhibitors exert similar effects on the renin-angiotensin system. In several dozen published cases, ACE inhibitor use during the second and third trimesters of pregnancy was associated with fetal and neonatal injury, including <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, neonatal skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, reversible or <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">irreversible renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">Oligohydramnios</span> was also reported, presumably from decreased fetal renal function. In this setting, <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> was associated with fetal limb <span class="product-label-link" type="condition" conceptid="4208264" conceptname="Muscle contracture">contractures</span>, craniofacial deformation, and hypoplastic lung development. <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">Prematurity</span>, <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">intrauterine growth retardation</span>, and <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span> were also reported, although it is not clear whether these occurrences were due to exposure to the drug. In a retrospective study, first trimester use of ACE inhibitors, a specific class of drugs acting on the renin angiotensin system, was associated with a potential risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>.</p>
<p>When pregnancy occurs in a patient using Exforge HCT, the physician should discontinue Exforge HCT treatment as soon as possible. The physician should inform the patient about potential risks to the fetus based on the time of gestational exposure to Exforge HCT (first trimester only or later). If exposure occurs beyond the first trimester, an ultrasound examination should be done.</p>
<p>In rare cases when another antihypertensive agent can not be used to treat the pregnant patient, serial ultrasound examinations should be performed to assess the intraamniotic environment. Routine fetal testing with non-stress tests, biophysical profiles, and/or contraction stress tests may be appropriate based on gestational age and standards of care in the community. If <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> occurs in these situations, individualized decisions about continuing or discontinuing Exforge HCT treatment and about pregnancy management should be made by the patient, her physician, and experts in the management of high risk pregnancy. Patients and physicians should be aware that <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> may not appear until after the fetus has sustained irreversible injury.</p>
<p>Infants with histories of in utero exposure to Exforge HCT should be closely observed for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. If <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> occurs, these infants may require blood pressure and renal perfusion support. Exchange transfusion or dialysis may be required to reverse <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or support decreased renal function.</p>
<p>Healthcare professionals who prescribe drugs acting directly on the renin angiotensin system should counsel women of childbearing potential about the risks of these agents during pregnancy [see<span class="Italics"> Nonclinical Toxicology </span>(13.3)].</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.2"></a><p></p>
<h2>
<span class="Bold">8.3 </span><span class="Bold">Nursing Mothers</span>
</h2>
<p class="First">It is not known whether amlodipine and valsartan are excreted in human milk, but thiazides are excreted in human milk and valsartan is excreted in rat milk. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.3"></a><p></p>
<h2>
<span class="Bold">8.4 </span><span class="Bold">Pediatric Use</span>
</h2>
<p class="First">The safety and effectiveness of Exforge HCT in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.4"></a><p></p>
<h2>
<span class="Bold">8.5 </span><span class="Bold">Geriatric Use</span>
</h2>
<p class="First">In controlled clinical trials, 82 hypertensive patients treated with Exforge HCT wereÂ â‰¥65 years and 13 wereÂ â‰¥75 years. No overall differences in the efficacy or safety of Exforge HCT were observed in this patient population, but greater sensitivity of some older individuals cannot be ruled out.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1><span class="Bold">10  OVERDOSAGE</span></h1>
<p class="First">Limited data are available related to overdosage in humans. The most likely manifestations of overdosage would be <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> could occur from parasympathetic (vagal) stimulation. If symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> should occur, supportive treatment should be instituted.</p>
<p><span class="Bold">Amlodipine</span></p>
<p>Single oral doses of amlodipine maleate equivalent to 40 mg/kg and 100 mg/kg amlodipine in mice and rats, respectively, caused <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>. Single oral doses equivalent to 4 or more mg/kg amlodipine in dogs (11 or more times the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis) caused a marked peripheral vasodilation and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
<p>Overdosage might be expected to cause excessive peripheral vasodilation with marked <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. In humans, experience with intentional overdosage of amlodipine is limited. Reports of intentional overdosage include a patient who ingested 250 mg and was asymptomatic and was not hospitalized; another (120 mg) who was hospitalized underwent gastric lavage and remained normotensive; the third (105 mg) was hospitalized and had <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (90/50 mmHg) which normalized following plasma expansion. A case of accidental drug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> has been documented in a 19-month-old male who ingested 30 mg amlodipine (about 2 mg/kg). During the emergency room presentation, vital signs were stable with no evidence of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, but a heart rate of 180 bpm. Ipecac was administered 3.5 hours after ingestion and on subsequent observation (overnight) no sequelae were noted.</p>
<p>If massive <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should occur, active cardiac and respiratory monitoring should be instituted. Frequent blood pressure measurements are essential. Should <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occur, cardiovascular support including elevation of the extremities and the judicious administration of fluids should be initiated. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> remains unresponsive to these conservative measures, administration of vasopressors (such as phenylephrine) should be considered with attention to circulating volume and urine output. Intravenous calcium gluconate may help to reverse the effects of calcium entry blockade. As amlodipine is highly protein bound, hemodialysis is not likely to be of benefit.</p>
<p><span class="Bold">Valsartan</span></p>
<p><span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">Depressed level of consciousness</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> have been reported.</p>
<p>Valsartan is not removed from the plasma by hemodialysis.</p>
<p>Valsartan was without grossly observable adverse effects at single oral doses up to 2000 mg/kg in rats and up to 1000 mg/kg in marmosets, except for the <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> in the rat and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in the marmoset at the highest dose (60 and 31 times, respectively, the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis). (Calculations assume an oral dose of 320 mg/day and a 60-kg patient.)</p>
<p><span class="Bold">Hydrochlorothiazide</span></p>
<p>The degree to which hydrochlorothiazide is removed by hemodialysis has not been established. The most common signs and symptoms observed in patients are those caused by <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span> (<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4016089" conceptname="Hypochloremia">hypochloremia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>) and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> resulting from excessive <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>. If digitalis has also been administered, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> may accentuate <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</p>
<p>The oral LD<span class="Sub">50 </span>of hydrochlorothiazide is greater than 10Â g/kg in both mice and rats, 2000 and 4000 times, respectively, the maximum recommended human dose on aÂ mg/m<span class="Sup">2 </span>basis. (Calculations assume an oral dose of 25Â mg/day and a 60-kg patient.)</p>
<p><span class="Bold">Valsartan and Hydrochlorothiazide</span></p>
<p>In rats and marmosets, single oral doses of valsartan up to 1524 and 762Â mg/kg in combination with hydrochlorothiazide at doses up to 476 and 238Â mg/kg, respectively, were very well tolerated without any treatment-related effects. These no adverse effect doses in rats and marmosets, respectively, represent 46.5 and 23 times the maximum recommended human dose (MRHD) of valsartan and 188 and 113 times the MRHD of hydrochlorothiazide on aÂ mg/m<span class="Sup">2 </span>basis. (Calculations assume an oral dose of 320Â mg/day valsartan in combination with 25Â mg/day hydrochlorothiazide and a 60-kg patient.)</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1><span class="Bold">11  DESCRIPTION</span></h1>
<p class="First">Exforge HCT is a fixed combination of amlodipine, valsartan and hydrochlorothiazide.</p>
<p>Exforge HCT contains the besylate salt of amlodipine, a dihydropyridine calcium channel blocker (CCB). Amlodipine besylate, USP is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow crystalline powder, slightly soluble in water and sparingly soluble in ethanol. Amlodipine besylateâ€™s chemical name is 3-Ethyl 5-methyl (Â±)-2-[(2-aminoethoxy)methyl]-4-(<span class="Italics">o</span>-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate, monobenzenesulfonate ; its structural formula is</p>
<p><img alt="amlodipine structural formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=782bcaf4-0aa4-4527-b36f-d350ceb95637&amp;name=exforge-hct-01.jpg"></p>
<p>Its empirical formula is C<span class="Sub">20</span>H<span class="Sub">25</span>ClN<span class="Sub">2</span>O<span class="Sub">5</span>â€¢C<span class="Sub">6</span>H<span class="Sub">6</span>O<span class="Sub">3</span>S and its molecular weight is 567.1.</p>
<p>Valsartan, USP is a nonpeptide, orally active, and specific angiotensin II antagonist acting on the AT<span class="Sub">1</span> receptor subtype. Valsartan is a white to practically white fine powder, soluble in ethanol and methanol and slightly soluble in water. Valsartanâ€™s chemical name is N-(1-oxopentyl)-N-[[2â€²-(1<span class="Italics">H</span>-tetrazol-5-yl) [1,1â€²-biphenyl]-4-yl]methyl]-L-valine; its structural formula is</p>
<p><img alt="Valsartan structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=782bcaf4-0aa4-4527-b36f-d350ceb95637&amp;name=exforge-hct-02.jpg"></p>
<p>Its empirical formula is C<span class="Sub">24</span>H<span class="Sub">29</span>N<span class="Sub">5</span>O<span class="Sub">3</span> and its molecular weight is 435.5.</p>
<p>Hydrochlorothiazide, USP is a white, or practically white, practically odorless, crystalline powder. It is slightly soluble in water; freely soluble in sodium hydroxide solution, in <span class="Italics">n</span>-butylamine, and in dimethylformamide; sparingly soluble in methanol; and insoluble in ether, in chloroform, and in dilute mineral acids. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro-2<span class="Italics">H</span>-1,2,4-benzothiadiazine-7- sulfonamide 1,1-dioxide.</p>
<p>Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C<span class="Sub">7</span>H<span class="Sub">8</span>ClN<span class="Sub">3</span>O<span class="Sub">4</span>S<span class="Sub">2</span>, its molecular weight is 297.73, and its structural formula is</p>
<p><img alt="Hydrochlorothiazide structural formula " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=782bcaf4-0aa4-4527-b36f-d350ceb95637&amp;name=exforge-hct-03.jpg"></p>
<p>Exforge HCT film-coated tablets are formulated in five strengths for oral administration with a combination of amlodipine besylate,Â valsartan and hydrochlorothiazide, providing for the following available combinations: 5/160/12.5 mg, 10/160/12.5 mg, 5/160/25 mg, 10/160/25 mg and 10/320/25 mg amlodipine besylate/valsartan/hydrochlorothiazide. The inactive ingredients for all strengths of the tablets includeÂ microcrystalline cellulose; crospovidone; colloidal anhydrous silica; magnesium stearate; hypromellose, macrogol 4000 and talc. Additionally, the 5/160/12.5 mg strength contains titanium dioxide; the 10/160/12.5 mg strength contains titanium dioxide and yellow and red iron oxides; the 5/160/25 mg strength contains titanium dioxide and yellow iron oxide and the 10/160/25 mg and 10/320/25 mg strengths both contain yellow iron oxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1><span class="Bold">12  CLINICAL PHARMACOLOGY</span></h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2>
<span class="Bold">12.1 </span><span class="Bold">Mechanism of Action</span>
</h2>
<p class="First">The active ingredients of Exforge HCT target three separate mechanisms involved in blood pressure regulation. Specifically, amlodipine blocks the contractile effects of calcium on cardiac and vascular smooth muscle cells; valsartan blocks the <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> and sodium retaining effects of angiotensin II on cardiac, vascular smooth muscle, adrenal and renal cells; and hydrochlorothiazide directly promotes the excretion of sodium and chloride in the kidney leading to reductions in intravascular volume. A more detailed description of the mechanism of action of each individual component follows.</p>
<p><span class="Bold">Amlodipine</span></p>
<p>Amlodipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Negative inotropic effects can be detected in vitro but such effects have not been seen in intact animals at therapeutic doses. Serum calcium concentration is not affected by amlodipine. Within the physiologic pH range, amlodipine is an ionized compound (pKa=8.6), and its kinetic interaction with the calcium channel receptor is characterized by a gradual rate of association and dissociation with the receptor binding site, resulting in a gradual onset of effect.</p>
<p>Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and reduction in blood pressure.</p>
<p><span class="Bold">Valsartan</span></p>
<p>Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Valsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT<span class="Sub">1</span> receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin II synthesis.</p>
<p>There is also an AT<span class="Sub">2</span> receptor found in many tissues, but AT<span class="Sub">2</span> is not known to be associated with cardiovascular homeostasis. Valsartan has much greater affinity (about 20,000-fold) for the AT<span class="Sub">1</span> receptor than for the AT<span class="Sub">2</span> receptor. The increased plasma levels of angiotensin following AT<span class="Sub">1</span> receptor blockade with valsartan may stimulate the unblocked AT<span class="Sub">2</span> receptor. The primary metabolite of valsartan is essentially inactive with an affinity for the AT<span class="Sub">1</span> receptor about one-200th that of valsartan itself.</p>
<p>Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is widely used in the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. ACE inhibitors also inhibit the degradation of bradykinin, a reaction also catalyzed by ACE. Because valsartan does not inhibit ACE (kininase II), it does not affect the response to bradykinin. Whether this difference has clinical relevance is not yet known. Valsartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.</p>
<p>Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of valsartan on blood pressure.</p>
<p><span class="Bold">Hydrochlorothiazide</span></p>
<p>Hydrochlorothiazide is a thiazide diuretic. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium. The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.</p>
<p>The mechanism of the antihypertensive effect of thiazides is unknown.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-11.2"></a><p></p>
<h2>
<span class="Bold">12.2 </span><span class="Bold">Pharmacodynamics</span>
</h2>
<p class="First">Exforge HCT has been shown to be effective in lowering blood pressure. The three components of Exforge HCT (amlodipine, valsartan, hydrochlorothiazide) lower the blood pressure through complementary mechanisms, each working at a separate site and blocking different effector pathways. The pharmacodynamics of each individual component is described below.</p>
<p>Exforge HCT has not been studied in indications other than <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
<p><span class="Bold">Amlodipine</span></p>
<p>Following administration of therapeutic doses to patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, amlodipine produces vasodilation resulting in a reduction of supine and standing blood pressures. These decreases in blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with chronic dosing. Although the acute intravenous administration of amlodipine decreases arterial blood pressure and increases heart rate in hemodynamic studies of patients with chronic stable angina, chronic oral administration of amlodipine in clinical trials did not lead to clinically significant changes in heart rate or blood pressures in normotensive patients with angina.</p>
<p>With chronic once daily administration, antihypertensive effectiveness is maintained for at least 24 hours. Plasma concentrations correlate with effect in both young and elderly patients. The magnitude of reduction in blood pressure with amlodipine is also correlated with the height of pretreatment elevation; thus, individuals with moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (diastolic pressure 105-114 mmHg) had about a 50% greater response than patients with mild <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (diastolic pressure 90-104 mmHg). Normotensive subjects experienced no clinically significant change in blood pressure (+1/-2 mmHg).</p>
<p>In hypertensive patients with normal renal function, therapeutic doses of amlodipine resulted in a decrease in renal <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and an increase in glomerular filtration rate and effective renal plasma flow without change in filtration fraction or <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>.</p>
<p>As with other calcium channel blockers, hemodynamic measurements of cardiac function at rest and during exercise (or pacing) in patients with normal ventricular function treated with amlodipine have generally demonstrated a small increase in <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> without significant influence on dP/dt or on left ventricular end diastolic pressure or volume. In hemodynamic studies, amlodipine has not been associated with a negative inotropic effect when administered in the therapeutic dose range to intact animals and man, even when co-administered with beta-blockers to man. Similar findings, however, have been observed in normals or well-compensated patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> with agents possessing significant negative inotropic effects.</p>
<p>Amlodipine does not change sinoatrial nodal function or atrioventricular conduction in intact animals or man. In patients with chronic stable angina, intravenous administration of 10 mg did not significantly alter A-H and H-V conduction and sinus node recovery time after pacing. Similar results were obtained in patients receiving amlodipine and concomitant beta-blockers. In clinical studies in which amlodipine was administered in combination with beta-blockers to patients with either <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or angina, no adverse effects of electrocardiographic parameters were observed. In clinical trials with angina patients alone, amlodipine therapy did not alter electrocardiographic intervals or produce higher degrees of <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV blocks</span>.</p>
<p>Amlodipine has indications other than <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> which are described in its full prescribing information.</p>
<p><span class="Bold">Valsartan</span></p>
<p>Valsartan inhibits the pressor effect of angiotensin II infusions. An oral dose of 80 mg inhibits the pressor effect by about 80% at peak with approximately 30% inhibition persisting for 24 hours. No information on the effect of larger doses is available.</p>
<p>Removal of the negative feedback of angiotensin II causes a 2- to 3-fold rise in plasma renin and consequent rise in angiotensin II plasma concentration in hypertensive patients. Minimal decreases in plasma aldosterone were observed after administration of valsartan; very little effect on serum potassium was observed.</p>
<p>In multiple dose studies in hypertensive patients with stable <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> and patients with <span class="product-label-link" type="condition" conceptid="317895" conceptname="Renovascular hypertension">renovascular hypertension</span>, valsartan had no clinically significant effects on glomerular filtration rate, filtration fraction, creatinine clearance, or renal plasma flow.</p>
<p>Administration of valsartan to patients with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> results in a significant reduction of sitting, supine, and standing systolic blood pressure, usually with little or no orthostatic change.</p>
<p>Valsartan has indications other than <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> which are described in its full prescribing information.</p>
<p><span class="Bold">Hydrochlorothiazide</span></p>
<p>After oral administration of hydrochlorothiazide, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-11.3"></a><p></p>
<h2>
<span class="Bold">12.3 </span><span class="Bold">Pharmacokinetics</span>
</h2>
<p class="First"><span class="Bold">Exforge HCT</span></p>
<p>Following oral administration of Exforge HCT in normal healthy adults, peak plasma concentrations of amlodipine, valsartan and HCTZ are reached in about 6 hours, 3 hours, and 2 hours, respectively. The rate and extent of absorption of amlodipine, valsartan and HCTZ from Exforge HCT are the same as when administered as individual dosage forms.</p>
<p><span class="Bold">Amlodipine</span></p>
<p>Peak plasma concentrations of amlodipine are reached 6-12 hours after administration of amlodipine alone. Absolute bioavailability has been estimated to be between 64% and 90%. The apparent volume of distribution of amlodipine is 21 L/kg. Approximately 93% of circulating amlodipine is bound to plasma proteins in hypertensive patients.</p>
<p>Amlodipine is extensively (about 90%) converted to inactive metabolites via hepatic metabolism with 10% of the parent compound and 60% of the metabolites excreted in the urine.</p>
<p>Elimination of amlodipine from the plasma is biphasic with a terminal elimination half-life of about 30-50 hours. Steady state plasma levels of amlodipine are reached after 7 to 8 days of consecutive daily dosing. </p>
<p><span class="Bold">Valsartan</span></p>
<p>Following oral administration of valsartan alone peak plasma concentrations of valsartan are reached in 2 to 4 hours. Absolute bioavailability is aboutÂ 25% (range 10%-35%).</p>
<p>The steady state volume of distribution of valsartan after intravenous administration is 17 L indicating that valsartan does not distribute into tissues extensively. Valsartan is highly bound to serum proteins (95%), mainly serum albumin.</p>
<p>Valsartan shows bi-exponential decay kinetics following intravenous administration with an average elimination half-life of about 6 hours. The recovery is mainly as unchanged drug, with only about 20% of dose recovered as metabolites. The primary metabolite, accounting for about 9% of dose, is valeryl 4-hydroxy valsartan. In vitro metabolism studies involving recombinant CYP450 enzymes indicated that the CYP2C9 isoenzyme is responsible for the formation of valeryl-4-hydroxy valsartan.Â Valsartan does not inhibit CYP450 isozymes at clinically relevant concentrations. CYP450 mediated drug interaction between valsartan and co-administered drugs are unlikely because of the low extent of metabolism.</p>
<p>Valsartan, when administered as an oral solution, is primarily recovered in feces (about 83% of dose) and urine (about 13% of dose). Following intravenous administration, plasma clearance of valsartan is about 2 L/h and its renal clearance is 0.62 L/h (about 30% of total clearance).</p>
<p><span class="Bold">Hydrochlorothiazide</span></p>
<p>Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. At least 61% of the oral dose is eliminated as unchanged drug within 24 hours. The elimination half-life is between 5.8 and 18.9 hours. Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.</p>
<p><span class="Bold Italics">Geriatric</span></p>
<p><span class="Bold Italics">Studies with amlodipine:</span> Elderly patients have decreased clearance of amlodipine with a resulting increase in AUC of approximately 40%-60%; therefore a lower initial dose of amlodipine may be required.</p>
<p><span class="Bold Italics">Studies with valsartan:</span> Exposure (measured by AUC) to valsartan is higher by 70% and the half-life is longer by 35% in the elderly than in the young. No dosage adjustment is necessary.</p>
<p><span class="Bold Italics">Gender</span></p>
<p><span class="Bold Italics">Studies with valsartan:</span> Pharmacokinetics of valsartan does not differ significantly between males and females.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></span></p>
<p><span class="Bold Italics">Studies with amlodipine:</span> The pharmacokinetics of amlodipine is not significantly influenced by <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> may therefore receive the usual initial dose.</p>
<p><span class="Bold Italics">Studies with valsartan:</span> There is no apparent correlation between renal function (measured by creatinine clearance) and exposure (measured by AUC) to valsartan in patients with different degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Consequently, dose adjustment is not required in patients with mild-to-moderate renal dysfunction. No studies have been performed in patients with severe impairment of renal function (creatinine clearance &lt;10 mL/min). Valsartan is not removed from the plasma by hemodialysis. In the case of severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, exercise care with dosing of valsartan.</p>
<p><span class="Bold Italics">Studies with hydrochlorothiazide</span><span class="Bold Italics">: </span>The half-life of hydrochlorothiazide elimination was lengthened to 21 hours in a study of patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (mean creatinine clearance of 19 mL/min).</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></span></p>
<p><span class="Bold Italics">Studies with amlodipine:</span> Patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> have decreased clearance of amlodipine with resulting increase in AUC of approximately 40%-60%; therefore, a lower initial dose of amlodipine may be required.</p>
<p><span class="Bold Italics">Studies with valsartan:</span> On average, patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span> have twice the exposure (measured by AUC values) to valsartan of healthy volunteers (matched by age, sex and weight). In general, no dosage adjustment is needed in patients with mild-to-moderate liver disease. Care should be exercised in patients with liver disease. </p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1><span class="Bold">13  NONCLINICAL TOXICOLOGY</span></h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2>
<span class="Bold">13.1 </span><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</span>
</h2>
<p class="First"><span class="Bold Italics">Studies with amlodipine/valsartan/hydrochlorothiazide</span><span class="Bold">:</span> No carcinogenicity, mutagenicity or fertility studies have been conducted with this combination. However, these studies have been conducted for amlodipine, valsartan and hydrochlorothiazide alone. Based on the preclinical safety and human pharmacokinetic studies, there is no indication of any toxicologically significant adverse interaction between these components.</p>
<p><span class="Bold Italics">Studies with amlodipine:</span><span class="Italics">Â </span>Rats and mice treated with amlodipine maleate in the diet for up toÂ two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mgÂ amlodipine/kg/day, showed no evidence of a carcinogenic effect of the drug. For the mouse,Â the highest dose was, on mg/m<span class="Sup">2</span>Â basis, similar to the maximum recommended human doseÂ [MRHD] of 10 mg amlodipine/day. For the rat, the highest dose was, on a mg/m<span class="Sup">2 </span>basis, aboutÂ two and a half times the MRHD. (Calculations based on a 60 kg patient.)</p>
<p>Mutagenicity studies conducted with amlodipine maleate revealed no drug-related effects atÂ either the gene or chromosome level.</p>
<p>There was no effect on the fertility of rats treated orally with amlodipine maleate (males forÂ 64 days and females for 14 days prior to mating) at doses of up to 10 mg amlodipine/kg/dayÂ (about 10 times the MRHD of 10 mg/day on a mg/m<span class="Sup">2 </span>basis).</p>
<p><span class="Bold Italics">Studies with valsartan:</span><span class="Italics">Â </span>There was no evidence of carcinogenicity when valsartan wasÂ administered in the diet to mice and rats for up to 2 years at concentrations calculated toÂ provide doses of up to 160 and 200 mg/kg/day, respectively. These doses in mice and rats areÂ about 2.4 and 6 times, respectively, the MRHD of 320 mg/day on a mg/m<span class="Sup">2</span>Â basis.Â (Calculations based on a 60 kg patient.)</p>
<p>Mutagenicity assays did not reveal any valsartan-related effects at either the gene orÂ chromosome level. These assays included bacterial mutagenicity tests with <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> and E.Â coli, a gene mutation test with Chinese hamster V79 cells, a cytogenetic test with ChineseÂ hamster ovary cells, and a rat micronucleus test.</p>
<p>Valsartan had no adverse effects on the reproductive performance of male or female rats atÂ oral doses of up to 200 mg/kg/day. This dose is about 6 times the maximum recommendedÂ human dose on a mg/m<span class="Sup">2</span>Â basis.</p>
<p><span class="Bold Italics">Studies with hydrochlorothiazide</span><span class="Bold Italics">: </span>Two-year feeding studies in mice and rats conducted under the auspices of the National Toxicology Program (NTP) uncovered no evidence of a carcinogenic potential of hydrochlorothiazide in female mice (at doses of up to approximately 600Â mg/kg/day) or in male and female rats (at doses of up to approximately 100Â mg/kg/day). The NTP, however, found equivocal evidence for hepatocarcinogenicity in male mice.</p>
<p>Hydrochlorothiazide was not genotoxic <span class="Italics">in vitro </span>in the Ames mutagenicity assay of <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> Typhimurium <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> TAÂ 98, TA 100, TA 1535, TA 1537, and TA 1538 and in the Chinese Hamster Ovary (CHO) test for chromosomal aberrations, or <span class="Italics">in vivo </span>in assays using mouse germinal cell chromosomes, Chinese hamster bone marrow chromosomes, and the Drosophila sex-linked recessive lethal trait gene. Positive test results were obtained in the <span class="Italics">in vitro </span>CHO Sister Chromatid Exchange (clastogenicity) and Mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> Cell (mutagenicity) assays and in the Aspergillus Nidulans non-disjunction assay.</p>
<p>Hydrochlorothiazide had no adverse effects on the fertility of mice and rats of either sex in studies wherein these species were exposed via diet at doses of up to 100 and 4Â mg/kg, respectively, prior to mating and throughout gestation. These doses of hydrochlorothiazide in mice and rats are 19 and 1.5 times, respectively, the maximum recommended human dose on aÂ mg/m<span class="Sup">2 </span>basis. (Calculations assume an oral dose of 25Â mg/day and a 60-kg patient.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2"></a><p></p>
<h2>
<span class="Bold">13.3 </span><span class="Bold">Developmental Toxicity</span>
</h2>
<p class="First"><span class="Bold Italics">Studies with amlodipine:</span><span class="Italics">Â </span>No evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> or other embryo/fetal toxicity wasÂ found when pregnant rats and rabbits were treated orally with amlodipine maleate at doses of up to 10 mg amlodipine/kg/day (respectively, about 10 and 20 times the maximum recommended human dose [MRHD] of 10 mg amlodipine on a mg/m<span class="Sup">2</span> basis) during their respective periods of major organogenesis. (Calculations based on a patient weight of 60 kg.) However, litter size was significantly decreased (by about 50%) and the number of intrauterine <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> was significantly increased (about 5-fold) for rats receiving amlodipine maleate at a dose equivalent to 10 mg amlodipine/kg/day for 14 days before mating and throughout mating and gestation. Amlodipine maleate has been shown to prolong both the gestation period and the duration of labor in rats at this dose. There are no adequate and well controlled studies in pregnant women.</p>
<p><span class="Bold Italics">Studies with valsartan:</span><span class="Italics">Â </span>No teratogenic effects were observed when valsartan was administeredÂ to pregnant mice and rats at oral doses of up to 600 mg/kg/day and to pregnant rabbits at oral doses of up to 10 mg/kg/day. However, significant decreases in fetal weight, pup birth weight, pup survival rate, and slight delays in developmental milestones were observed in studies in which parental rats were treated with valsartan at oral, maternally toxic (reduction in body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and food consumption) doses of 600 mg/kg/day during organogenesis or late gestation and lactation. In rabbits, fetotoxicity (i.e., resorptions, litter loss, abortions, andÂ low body weight) associated with maternal toxicity (mortality) was observed at doses of 5 and 10 mg/kg/day. The no observed adverse effect doses of 600, 200 and 2 mg/kg/day in mice, rats and rabbits, respectively, are about 9, 6 and 0.1 times the MRHD of 320 mg/day on a mg/m<span class="Sup">2</span> basis. (Calculations based on a patient weight of 60 kg.)</p>
<p><span class="Bold Italics">Studies with hydrochlorothiazide</span><span class="Italics">:</span>Â Under the auspices of the National Toxicology Program, pregnant mice and rats that received hydrochlorothiazide via gavage at doses up to 3000 and 1000Â mg/kg/day, respectively, on gestation days 6 through 15 showed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. These doses of hydrochlorothiazide in mice and rats are 608 and 405 times, respectively, the maximum recommended human dose on aÂ mg/m<span class="Sup">2 </span>basis. (Calculations assume an oral dose of 25Â mg/day and a 60-kg patient.)</p>
<p><span class="Bold Italics">Studies with amlodipine and valsartan:</span><span class="Italics">Â </span>In the oral embryo-fetal development study in rats using amlodipine besylate plus valsartan at doses equivalent to 5 mg/kg/day amlodipine plus 80 mg/kg/day valsartan, 10 mg/kg/day amlodipine plus 160 mg/kg/day valsartan, and 20 mg/kg/day amlodipine plus 320 mg/kg/day valsartan, treatment-related maternal and fetal effects (<span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delays</span> and alterations noted in the presence of significant maternal toxicity) were noted with the high dose combination. The no-observed-adverse-effect level (NOAEL) for embryo- fetal effects was 10 mg/kg/day amlodipine plus 160 mg/kg/day valsartan. On a systemic exposure [AUC<span class="Sub">(0-âˆž)</span>] basis, these doses are, respectively, 4.3 and 2.7 times the systemic exposure [AUC<span class="Sub">(0-âˆž)</span>] in humans receiving the MRHD (10/320 mg/60 kg).</p>
<p><span class="Bold Italics">Studies with valsartan and hydrochlorothiazide</span><span class="Bold Italics">:</span> There was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in mice, rats, or rabbits treated orally with valsartan at doses up to 600, 100 and 10Â mg/kg/day, respectively, in combination with hydrochlorothiazide at doses up to 188, 31 and 3Â mg/kg/day. These non-teratogenic doses in mice, rats and rabbits are, respectively, 9, 3.5 and 0.5 times the maximum recommended human dose (MRHD) of valsartan and 38, 13 and 2 times the MRHD of hydrochlorothiazide on aÂ mg/m<span class="Sup">2 </span>basis. (Calculations assume an oral dose of 320Â mg/day valsartan in combination with 25Â mg/day hydrochlorothiazide in a 60-kg patient.)</p>
<p>Fetotoxicity was observed in association with maternal toxicity in rats at valsartan/hydrochlorothiazide doses â‰¥200/63 mg/kg/day andÂ in rabbits at valsartan/hydrochlorothiazide doses of 10/3Â mg/kg/day. Evidence of fetotoxicity in rats consisted of decreased fetal weight and fetal variations of sternebrae, vertebrae, ribs and/or renal papillae. Evidence of fetotoxicity in rabbits included increased numbers of late resorptions with resultant increases in total resorptions, postimplantation losses and decreased number of live fetuses. The no observed adverse effect doses of the valsartan/hydrochlorothiazide combination in mice, rats and rabbits were 600/188, 100/31 and 3/1Â mg/kg/day, respectively. These doses in mice, rats and rabbits are, respectively, 9, 3 and 0.18 times the MRHD ofÂ valsartan and 38, 13 and 0.5 times the MRHD of hydrochlorothiazide on aÂ mg/m<span class="Sup">2 </span>basis. (Calculations assume an oral dose of 320Â mg/day valsartan in combination with 25Â mg/day hydrochlorothiazide in a 60-kg patient.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>
<span class="Bold">14 </span><span class="Bold">Â </span><span class="Bold">CLINICAL STUDIES</span>
</h1>
<p class="First">Exforge HCT was studied in a double-blind, active controlled study in hypertensive patients. A total of 2,271 patients with moderate to severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (mean baseline systolic/diastolic blood pressure was 170/107 mmHg) received treatments of amlodipine/valsartan/HCTZ 10/320/25 mg,Â valsartan/HCTZ 320/25 mg, amlodipine/valsartan 10/320 mg, or HCTZ/amlodipine 25/10 mg. At study initiation patients assigned to the two-component arms received lower doses of their treatment combination while patients assigned to the Exforge HCT arm received 160/12.5 mg valsartan/hydrochlorothiazide. After one week, Exforge HCT patients were titrated to 5/160/12.5 mg amlodipine/valsartan/hydrochlorothiazide, while all other patients continued receiving their initial doses. After two weeks, all patients were titrated to their full treatment dose. A total of 55% of patients were male, 14%Â were 65 years or older, 72% were Caucasian, and 17% were Black.</p>
<p>At week 8, the triple combination therapy produced greater reductions in blood pressure than each of the three dual combination treatments (p&lt;0.0001 for both diastolic and systolic blood pressures reductions). The reductions in systolic/diastolic blood pressure with Exforge HCT were 7.6/5.0 mmHg greater than with valsartan/HCTZ, 6.2/3.3 mmHg greater than with amlodipine/valsartan, and 8.2/5.3 mmHg greater than with amlodipine/HCTZ (see Figure 1). The full blood pressure lowering effect was achieved 2 weeks after being on the maximal dose of Exforge HCT (see Figure 2 and Figure 3). As the pivotal study was an active controlled trial, the treatment effects shown in Figure 1, 2, and 3 include a placebo effect of unknown size.</p>
<div class="Figure">
<img alt="Figure 1: Reduction in Mean Blood Pressure at Endpoint" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=782bcaf4-0aa4-4527-b36f-d350ceb95637&amp;name=exforge-hct-04.jpg"><p class="MultiMediaCaption">Figure 1: Reduction in Mean Blood Pressure at Endpoint</p>
</div>
<div class="Figure">
<img alt="Figure 2: Mean Sitting Diastolic Blood Pressure by Treatment and Week" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=782bcaf4-0aa4-4527-b36f-d350ceb95637&amp;name=exforge-hct-05.jpg"><p class="MultiMediaCaption">Figure 2: Mean Sitting Diastolic Blood Pressure by Treatment and Week</p>
</div>
<div class="Figure">
<img alt="Figure 3: Mean Sitting Systolic Blood Pressure by Treatment and Week" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=782bcaf4-0aa4-4527-b36f-d350ceb95637&amp;name=exforge-hct-06.jpg"><p class="MultiMediaCaption">Figure 3: Mean Sitting Systolic Blood Pressure by Treatment and Week</p>
</div>
<p>A subgroup of 283Â patients was studied with ambulatory blood pressure monitoring. The blood pressure lowering effect in the triple therapy group was maintained throughout the 24-hour period (see Figure 4 and Figure 5).</p>
<div class="Figure">
<img alt="Figure 4: Mean Ambulatory Diastolic Blood Pressure at Endpoint by Treatment and Hour" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=782bcaf4-0aa4-4527-b36f-d350ceb95637&amp;name=exforge-hct-07.jpg"><p class="MultiMediaCaption">Figure 4: Mean Ambulatory Diastolic Blood Pressure at Endpoint by Treatment and Hour</p>
</div>
<div class="Figure">
<img alt="Figure 5: Mean Ambulatory Systolic Blood Pressure at Endpoint by Treatment and Hour" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=782bcaf4-0aa4-4527-b36f-d350ceb95637&amp;name=exforge-hct-08.jpg"><p class="MultiMediaCaption">Figure 5: Mean Ambulatory Systolic Blood Pressure at Endpoint by Treatment and Hour</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1><span class="Bold">16  HOW SUPPLIED/STORAGE AND HANDLING</span></h1>
<p class="First">Exforge HCT (amlodipine, valsartan, hydrochlorothiazide) is available as film-coated tablets containing amlodipine besylate equivalent to 10 mg of amlodipine free-base with valsartan 320 mg and hydrochlorothiazide 25 mg, providing for the following available combination: 10/320/25 mg. <br></p>
<br><p><span class="Bold">10 mg amlodipine /320 mg valsartan /25 mg hydrochlorothiazide Tablets </span>â€“ Brown-yellow, non-scored, film-coated tablet, ovaloid, biconvex with beveled edge with debossing â€œNVRâ€? on one side and â€œVFLâ€? on the other side.</p>
<a name="i8a6da40c-6868-4611-81cf-7b97df41bbb5"></a><table width="30%"><tbody class="Headless"><tr class="First Last">
<td>Bottles of 30<br>
</td>
<td>NDC 54868-6123-0<br>
</td>
</tr></tbody></table>
<p><br></p>
<p>Store at 25Â°C (77Â°F); excursions permitted to 15-30Â°C (59-86Â°F), [see USP controlled room temperature.]</p>
<p>Protect from moisture.</p>
<p>Dispense in tight container (USP).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1><span class="Bold">17  PATIENT COUNSELING INFORMATION</span></h1>
<p class="First"><span class="Bold Italics">Pregnancy:</span> Female patients of childbearing age should be told that use of drugs like Exforge HCT that act on the renin-angiotensin system during pregnancy can cause serious problems in the fetus and infant including: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span>, poor development of skull bones, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Discuss other treatment options with female patients planning to become pregnant. Women using Exforge HCT who become pregnant should notify their physician as soon as possible.</p>
<p><span class="Bold Italics">Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span><span class="Bold Italics">: </span>A patient receiving Exforge HCT should be cautioned that <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> can occur, especially during the first days of therapy, and that it should be reported to the prescribing physician. The patients should be told that if <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> occurs, Exforge HCT should be discontinued until the physician has been consulted.</p>
<p>All patients should be cautioned that inadequate fluid intake, excessive perspiration, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> can lead to an excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span>, with the same consequences of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> and possible <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
<p><span class="Bold Italics">Potassium Supplements</span><span class="Bold Italics">: </span>A patient receiving Exforge HCT should be told not to use potassium supplements or salt substitutes containing potassium without consulting the prescribing physician. </p>
<p><span class="Bold">Information for Patients</span></p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold Italics">Patient Information</span></p>
<p><span class="Bold">Exforge HCT (X-phorj HCT)</span><br>(amlodipine and valsartan and hydrochlorothiazide) Tablets</p>
<p>Read the Patient Information that comes with EXFORGE HCT before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your medical condition or treatment.</p>
<p><span class="Bold">What is the most important information I should know about EXFORGE HCT?</span></p>
<p><span class="Bold">If you become pregnant while taking EXFORGE HCT, stop taking EXFORGE HCT and call your doctor right away</span><span class="Bold">. </span><span class="Bold">EXFORGE HCT can harm an unborn baby causing injury or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span><span class="Bold">.</span> Talk to your doctor about other treatment options to lower your blood pressure before taking EXFORGE HCT if you plan to become pregnant.</p>
<p><span class="Bold">What is EXFORGE HCT?</span></p>
<p>EXFORGE HCT contains three prescription medicines:</p>
<ol class="Arabic">
<li>amlodipine, a calcium channel blocker<br>
</li>
<li>valsartan, an angiotensin receptor blocker, and<br>
</li>
<li>hydrochlorothiazide, a diuretic (water pill)</li>
</ol>
<p>EXFORGE HCT may be used to lower blood pressure in adults when two medicines to lower your high blood pressure are not enough.</p>
<p>EXFORGE HCT has not been studied in children under 18 years of age.</p>
<p><span class="Bold">Who should not take EXFORGE HCT?</span></p>
<p><span class="Bold">Do not take EXFORGE HCT if you have low or no urine output (<span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>).</span></p>
<p><span class="Bold">What should I tell my doctor before taking EXFORGE HCT?</span></p>
<p>Tell your doctor about all of your medical conditions, including if you: </p>
<ul class="Disc">
<li>
<span class="Bold">are pregnant or plan to become pregnant</span><span class="Bold">.</span> See â€œWhat is the most important information I should know about EXFORGE HCT?â€?<br>
</li>
<li>
<span class="Bold">are breast-feeding or plan to breast-feed.</span> EXFORGE HCT may pass into your milk. Do not breast-feed while you are taking EXFORGE HCT.<br>
</li>
<li>are allergic to any of the ingredients in EXFORGE HCT. See the end of this leaflet for a list of the ingredients in EXFORGE HCT.<br>
</li>
<li>have heart problems<br>
</li>
<li>have liver problems <br>
</li>
<li>have kidney problems<br>
</li>
<li>are <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or having a lot of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> <br>
</li>
<li>have or had <span class="product-label-link" type="condition" conceptid="196456" conceptname="Gallstone">gallstones</span><br>
</li>
<li>have Lupus</li>
</ul>
<p>Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. Some of your other medicines and EXFORGE HCT could affect each other, causing serious side effects. </p>
<p>Especially tell your doctor if you take: </p>
<ul class="Disc">
<li>other medicines for high blood pressure or a heart problem<br>
</li>
<li>water pills (â€œdiureticsâ€?) <br>
</li>
<li>potassium supplements or using a salt substitute containing potassium<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicine including insulin<br>
</li>
<li>narcotic <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicines<br>
</li>
<li>sleeping pills and anti-<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> medicines called barbiturates<br>
</li>
<li>lithium, a medicine used to treat some types of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span><br>
</li>
<li>aspirin or other medicines called non-steriodal anti-inflammatory drugs (NSAIDs)<br>
</li>
<li>steroids<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> lowering medicine<br>
</li>
<li>alcohol</li>
</ul>
<p>Know the medicines you take. Keep a list of your medicines and show it to your doctor or pharmacist when you get a new medicine. </p>
<p><span class="Bold">How should I take EXFORGE HCT?</span></p>
<ul class="Disc">
<li>Take EXFORGE HCT exactly as your doctor tells you.<br>
</li>
<li>Take EXFORGE HCT one time each day.<br>
</li>
<li>EXFORGE HCT can be taken with or without food.<br>
</li>
<li>If you miss a dose, take it as soon as you remember. If it is close to your next dose, do not take the missed dose. Just take the next dose at the regular time. <br>
</li>
<li>If you take too much EXFORGE HCT, call your doctor or Poison Control Center, or go to the emergency room.<br>
</li>
<li>Tell all your doctors and dentist you are taking EXFORGE HCT. This is especially important if you:<ul class="Circle">
<li>are going to have surgery<br>
</li>
<li>go for kidney dialysis</li>
</ul>
</li>
</ul>
<p><span class="Bold">What are the possible side effects of EXFORGE HCT?</span></p>
<p>EXFORGE HCT may cause <span class="Bold">serious side effects</span> including:</p>
<ul class="Disc">
<li>
<span class="Bold">harm to an unborn baby causing injury or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span><span class="Bold">. </span><span class="Bold">See â€œWhat is the most important information I should know about EXFORGE HCT?â€?</span><br>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span></span> (<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>). <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Low blood pressure</span> is most likely to happen if you:<ul class="Circle">
<li>take water pills<br>
</li>
<li>are on a low salt diet<br>
</li>
<li>have heart problems<br>
</li>
<li>get dialysis treatments<br>
</li>
<li>get sick with <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span><br>
</li>
<li>drink alcohol.</li>
</ul>
</li>
</ul>
<p>Lie down if you feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> or dizzy. If you <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> (lose consciousness), stop taking EXFORGE HCT. Call your doctor right away.</p>
<ul class="Disc">
<li>Get emergency help if you get worse <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> that does not go away. <br>
</li>
<li>
<span class="Bold">kidney problems.</span> Kidney problems may become worse in people that already have kidney disease. Some people will have changes in blood tests for kidney function and may need a lower dose of EXFORGE HCT. Call your doctor if you have <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in your feet, ankles, or hands, or unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. If you have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, your doctor should check your kidney function before prescribing EXFORGE HCT.<br>
</li>
<li>
<span class="Bold">laboratory blood test changes in people with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span></span>. Some people with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> who take valsartan, one of the medicines in EXFORGE HCT, have changes in blood tests including increased potassium and decreased kidney function.<br>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></span><br>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>. </span>Call your doctor right away if you get an unusual <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>. </li>
<li>
<span class="Bold">eye problems. </span>One of the medicines in EXFORGE HCT can cause eye problems that may lead to <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span>.  Symptoms of eye problems can happen within hours to weeks of starting EXFORGE HCT.  Tell your doctor right away if you have: <ul class="Disc">
<li>decrease in vision<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span></li>
</ul>
</li>
</ul>
<p>The <span class="Bold">most common</span> side effects of EXFORGE HCTÂ include:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> <br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> (<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>) of the hands, ankles, or feet<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.</li>
</ul>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of EXFORGE HCT. For more information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store EXFORGE HCT?</span></p>
<ul class="Disc">
<li>Store EXFORGE HCT at room temperature between 59Â°F to 86Â°F (15Â°C to 30Â°C). <br>
</li>
<li>Keep EXFORGE HCT dry (protect it from moisture). </li>
</ul>
<p><span class="Bold">Keep EXFORGE HCT and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General Information about EXFORGE HCT</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in the patient information leaflet. Do not use EXFORGE HCT for a condition for which it was not prescribed. Do not give EXFORGE HCT to other people, even if they have the same symptoms that you have. It may harm them. </p>
<p>This patient information leaflet summarizes the most important information about EXFORGE HCT. If you would like more information about EXFORGE HCT, talk with your doctor. You can ask your doctor or pharmacist for information about EXFORGE HCT that is written for health professionals. For more information go to www.EXFORGE.com or call 1-888-839-3674.Â </p>
<p><span class="Bold">What are the ingredients in EXFORGE HCT?</span></p>
<p>Active ingredients: amlodipine besylate, valsartan and hydrochlorothiazide</p>
<p>The inactive ingredients of all strengths of the tablets are crospovidone, magnesium stearate, microcrystalline cellulose, and colloidal anhydrous silica. The film coating contains hypromellose, talc, macrogol 4000 and may contain titanium dioxide or yellow and red iron oxides.</p>
<p><span class="Bold">What is high blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>)?</span></p>
<p>Blood pressure is the force of blood in your blood vessels when your heart beats and when your heart rests. You have high blood pressure when the force is too much. EXFORGE HCT can help your blood vessels relax so your blood pressure is lower. Drugs that lower blood pressure lower your chance of having a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>. </p>
<p>High blood pressure makes the heart work harder to pump blood throughout the body and causes damage to blood vessels. If high blood pressure is not treated, it can lead to <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span> and vision problems. </p>
<p>Distributed by:</p>
<p>Novartis Pharmaceuticals Corporation</p>
<p>East Hanover, New Jersey 07936</p>
<p>Â©Â Novartis</p>
<p>T2011-134/T2011-97</p>
<p>October 2011/February 2011</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<p class="First">Additional barcode label applied by:<br>Physicians Total Care, Inc.<br>Tulsa, OklahomaÂ Â Â  74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">Package Label â€“ </span><span class="Bold">10</span><span class="Bold"> mg</span><span class="Bold"> / 32</span><span class="Bold">0 mg / 25 mg</span></p>
<p>Rx Only
		Â Â Â Â Â 
	
		Â Â Â Â Â  <br></p>
<p>Exforge HCTÂ® </p>
<p>(amlodipine, valsartan, hydrochlorothiazide)</p>
<p>10 mg* / 320 mg / 25 mg</p>
<p>*each tablet contains 13.9 mg of amlodipine besylate</p>
<p>30 Tablets</p>
<p><img alt="PRINCIPAL DISPLAY PANEL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=782bcaf4-0aa4-4527-b36f-d350ceb95637&amp;name=package%20label.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EXFORGE HCTÂ 		
					</strong><br><span class="contentTableReg">amlodipine valsartan and hydrochlorothiazide tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6123(NDC:0078-0563)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">10Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>VALSARTAN</strong> (VALSARTAN) </td>
<td class="formItem">VALSARTAN</td>
<td class="formItem">320Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">25Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (brown-yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (ovaloid, biconvex tablets with beveled edge) </td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">NVR;VFL</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6123-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022314</td>
<td class="formItem">05/14/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8bc4df4b-1f3b-46a4-a17a-011d24b1e2b9</div>
<div>Set id: 782bcaf4-0aa4-4527-b36f-d350ceb95637</div>
<div>Version: 3</div>
<div>Effective Time: 20111219</div>
</div>
</div>Â <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
